In addition to the viral delivery of functional laforin or malin, the therapeutic options for Lafora disease include intracellular degradation of Lafora bodies by glucan-degrading enzymes such as α-amylase, as well as the downregulation of glycogen synthesis by targeting glycogen synthase (GS) or protein phosphatase 1 (PP1) subunit R5 at the gene, RNA or protein level. ASOs, antisense oligonucleotides; RNAi, RNA interference.